Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin.

Wilkins BW, Chung LH, Tublitz NJ, Wong BJ, Minson CT

Journal of applied physiology (Bethesda, Md. : 1985)21 May 2004Cited by 48 (Europe PMC)

PMID15155712DOI10.1152/japplphysiol.00366.2004PepBankPUB-15155712

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialMechanism
In human skin, VIP-mediated vasodilation includes a NO-dependent component at doses above 100 pmol, where NO synthase inhibition significantly attenuated cutaneous vascular conductance.
In plain wordsIn human skin, VIP-induced vessel widening partly depends on nitric oxide at doses above 100 pmol.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseNitric oxide contribution to VIP-mediated vasodilation
Study
n: not reported in source
Comparator
Without NO synthase inhibition
Outcome group
Vascular function · Cardiovascular
Studied dose
25-800 pmol · intradermal microdialysisAs given in this study (human).
Measurements
Dose threshold for NO-dependent component
> 100 pmol
VIP
Source sentences
Summary
VIP-mediated vasodilation includes a NO-dependent component at doses above 100 pmol, where NO synthase inhibition significantly attenuates CVC (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Study 1 examined the contribution of NO in the skin blood flow response to eight doses of VIP ranging from 25 to 800 pmol.
Summary · context
Forty-three subjects volunteered to participate in two studies designed to examine the mechanism of VIP-mediated vasodilation in human skin.
Summary · context
Infusions were administered to skin sites via intradermal microdialysis.
Report a problemFND-1515571201
02HumanNon-randomized trialMechanism
In human skin, inhibition of H1 receptors attenuated the rise in cutaneous vascular conductance to exogenous VIP.
In plain wordsIn human skin, blocking histamine H1 receptors reduced the vessel widening caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseHistamine H1 receptor contribution to VIP-mediated vasodilation
Study
n: not reported in source
Comparator
Without H1 inhibition
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intradermal microdialysisAs given in this study (human).
Source sentences
Summary
Inhibition of H1 receptors attenuates the rise in CVC to exogenous VIP (P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three subjects volunteered to participate in two studies designed to examine the mechanism of VIP-mediated vasodilation in human skin.
Summary · context
Infusions were administered to skin sites via intradermal microdialysis.
Report a problemFND-1515571202
03HumanNon-randomized trialMechanism
In human skin, combined H1-receptor and NO synthase inhibition reduced VIP-mediated vasodilation further than either inhibitor alone.
In plain wordsIn human skin, blocking both histamine H1 receptors and nitric oxide reduced VIP-induced vessel widening more than blocking either one alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseCombined H1 and NO synthase inhibition on VIP-mediated vasodilation
Study
n: not reported in source
Comparator
H1 inhibition alone or NO synthase inhibition alone
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intradermal microdialysisAs given in this study (human).
Source sentences
Summary
however, combined H1-receptor inhibition and NO synthase inhibition further reduced VIP-mediated vasodilation compared with either H1 inhibition or NO synthase inhibition alone (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three subjects volunteered to participate in two studies designed to examine the mechanism of VIP-mediated vasodilation in human skin.
Summary · context
Infusions were administered to skin sites via intradermal microdialysis.
Report a problemFND-1515571203
04HumanNon-randomized trialMechanism
In human skin, H2-receptor inhibition did not affect vasodilation to exogenous VIP.
In plain wordsIn human skin, blocking histamine H2 receptors did not change the vessel widening caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHistamine H2 receptor contribution to VIP-mediated vasodilation
Study
n: not reported in source
Comparator
Without H2 inhibition
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intradermal microdialysisAs given in this study (human).
Source sentences
Summary
In contrast to H1-receptor inhibition, H2-receptor inhibition did not affect vasodilation to exogenous VIP.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three subjects volunteered to participate in two studies designed to examine the mechanism of VIP-mediated vasodilation in human skin.
Summary · context
Infusions were administered to skin sites via intradermal microdialysis.
Report a problemFND-1515571204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.